Technology | November 23, 2009

New Ultrasound Thrombolysis System Introduced for DVT

November 23, 2009 – Using less lytic drug and offering faster clot dissolution than traditional deep vein thrombosis (DVT) treatments, EKOS Corp. launched the EkoSonic MACH4e at the recent VEITH Symposium in New York.

The MACH4e upgrade achieves faster removal of arterial and venous clots, which the company says accelerates thrombolysis by up to 40 percent (1). For simplicity, the new system automates a number of manual steps, making it easier to use.

The company said the system can be used to treat clots in veins, arteries, IVC filters and difficult-to-reach places such as behind valves. The ultrasound waves help increase drug uptake by the clot and uses 50-70 percent less lytic drug (3). The device reduces the risk pf thrombus fracture or breakage (4), reducing the risk of distal embolism, or post thrombotic syndrome (PTS).

During the Veith Symposium Mark J. Garcia, M.D., program director, vascular and interventional radiology fellowship and section chief, vascular and interventional radiology at Christiana Care Health Services in Newark, Del., presented a series of 35 patients with chronic, hard and occlusive DVT that were successfully treated with endovascular techniques. He said the EKOs system is a major breakthrough in restoring quality of life to the patient.

“The EKOS ultrasound assisted thrombolysis, in addition to standard angioplasty and stenting techniques, led to successful venous recanalization and patency with improved venous outflow,” said Dr. Garcia. “Our results suggest that the ability to successfully recanalize chronically occluded venous segments in patients with PTS, benefit the patient by reducing their symptoms and allowing them to enjoy an improved quality of life.”

EKOS pioneered the development and clinical application of ultrasonic accelerated drug delivery in medicine, introducing its first system for the treatment of vascular thrombosis in 2005. In 2008, the company introduced its second-generation EkoSonic Endovascular System with Rapid Pulse Modulation. In November 2009 introduced the MACH4e upgrade.

For more information:

1. EKOS in vitro data on file
2. Francis, CW, eta al. “Ultrasound Accelerates Transport of Recombinant tissue Plasminogen Activator into Clots.” Phys Med Biol, 2008.
3. Parikh, S., et al. “Ultrasound-Accelerated Thrombolysis for the Treatment of Deep Vein Thrombosis: Initial Clinical Experience.” Journal of Vascular and Interventional Radiology, April 2008, 19, pages 521-528.
4. Braatan, J., et al. “Ultrasound Reversibly Disaggregates Fibrin Fibers.” Thromb Haemost 78 (1997), pages 1063-8.

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init